Astrana Health (ASTH) Director Option Exercise and Issuer Share Repurchase Reported

Rhea-AI Filing Summary

Mitchell W. Kitayama, a director of Astrana Health, Inc. (ASTH), reported multiple transactions on 09/15/2025. He exercised 8,000 stock options with an $18.20 exercise price, resulting in the acquisition of 8,000 common shares. The filing also shows the issuer repurchased a total of 13,214 shares (8,000 and 5,214 reported disposals at $30.23 each). After these transactions, Kitayama beneficially owned 15,846 shares, which includes 6,449 restricted shares that vest on the earlier of June 11, 2026 or the date of the issuer's 2026 annual meeting. The options that were exercised were fully vested and exercisable and convert into 8,000 common shares.

Positive

• Exercised 8,000 stock options at an $18.20 exercise price resulting in acquisition of 8,000 common shares
• 6,449 restricted shares remain outstanding with a defined vesting schedule (earlier of June 11, 2026 or the 2026 annual meeting)

Negative

• Issuer repurchased 13,214 shares reported as disposals at $30.23, reducing the reporting person's beneficial ownership
• Beneficial ownership decreased to 15,846 shares following the transactions

Insights

Securities Analyst

TL;DR: Director exercised 8,000 options and acquired 8,000 shares; issuer repurchased 13,214 shares, leaving the director with 15,846 owned shares.

The filing documents a routine insider exercise and subsequent issuer repurchases. The exercised options had an $18.20 exercise price and converted into 8,000 common shares. The issuer repurchased shares at $30.23 per share in two disposal entries totaling 13,214 shares, reducing the reporting person's beneficial ownership from 29,060 to 15,846 shares. The remaining position includes 6,449 restricted shares that vest by mid-2026 or at the next annual meeting. These are non-derivative and derivative transactions typical of option exercises and share repurchase activity.

Corporate Governance Expert

TL;DR: Transactions reflect option exercise and issuer repurchases; restricted shares have a clear vesting timetable through mid-2026.

The report confirms the exercised stock options were fully vested and resulted in an immediate increase in common shares held by the director. The filing separately reports two disposals noted as repurchases by the issuer at $30.23 per share. The director's remaining beneficial ownership is explicitly stated and includes a tranche of restricted stock with a specified vesting trigger: the earlier of June 11, 2026 or the issuer's 2026 annual meeting. Documentation is properly signed by an attorney-in-fact as shown in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kitayama Mitchell W

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVE, 2ND FLOOR

(Street)

ALHAMBRA CA 91801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		M		8,000	A	$18.2	29,060	D
Common Stock	09/15/2025		D(1)		8,000	D	$30.23	21,060	D
Common Stock	09/15/2025		D(1)		5,214	D	$30.23	15,846(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$18.2	09/15/2025		M			8,000	(2)	11/11/2025	Common Stock	8,000	$0	12,000	D

Explanation of Responses:

1. These shares were repurchased by the Issuer.

2. These stock options were fully vested and exercisable.

3. Includes 6,449 shares of restricted stock, which will vest on the earlier of June 11, 2026 or the date of the Issuer's 2026 annual meeting of stockholders.

	/s/ Kathy Diep, as Attorney-in-Fact	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Mitchell W. Kitayama report on Form 4 for ASTH?

The Form 4 reports the exercise of 8,000 stock options at $18.20 (acquiring 8,000 shares) and two disposals totaling 13,214 shares repurchased by the issuer at $30.23.

How many ASTH shares does the reporting person own after the 09/15/2025 transactions?

After the reported transactions, the reporting person beneficially owns 15,846 shares.

Were the stock options fully vested before exercise?

Yes, the filing states the stock options were fully vested and exercisable prior to exercise.

Does the filing include any restricted stock and when does it vest?

Yes, the filing includes 6,449 restricted shares that vest on the earlier of June 11, 2026 or the date of the issuer's 2026 annual meeting of stockholders.

At what price were the repurchased shares reported?

The issuer repurchased the reported shares at $30.23 per share for the two disposal entries.